Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.58 |
| ▸ | NPC1 | O15118 | 6/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | CASP3 | P42574 | 1/20 | 0.58 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.58 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.58 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | APP | P05067 | 2/20 | 0.54 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | INSR | P06213 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28519023 | 0.98 | RAB9A (0.57) | RAB9ANPC1SMN1; SMN2LMNAALOX15 | |
| SCHEMBL13763546 | 0.84 | NPC1 (0.59) | RAB9ANPC1SMN1; SMN2LMNAALOX15 | |
| SCHEMBL10603259 | 0.84 | RAB9A (0.55) | RAB9ANPC1SMN1; SMN2LMNAALOX15 | |
| SCHEMBL30442434 | 0.84 | RAB9A (0.55) | RAB9ANPC1SMN1; SMN2LMNAALOX15 | |
| SCHEMBL21233552 | 0.82 | TSHR (0.58) | RAB9ANPC1SMN1; SMN2LMNAALOX15 | |
| SCHEMBL25474647 | 0.81 | RAB9A (0.53) | RAB9ANPC1SMN1; SMN2LMNAALOX15 | |
| SCHEMBL9037879 | 0.81 | NPC1 (0.53) | RAB9ANPC1SMN1; SMN2LMNAALOX15 | |
| SCHEMBL25514451 | 0.81 | RAB9A (0.53) | RAB9ANPC1SMN1; SMN2LMNAALOX15 | |
| SCHEMBL11676698 | 0.81 | RAB9A (0.61) | RAB9ANPC1SMN1; SMN2LMNAALOX15 | |
| SCHEMBL9474268 | 0.80 | RAB9A (0.51) | RAB9ANPC1SMN1; SMN2LMNAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112694453-B | Preparation method of N-methylated nitrogen-containing aromatic heterocyclic compound | 中国科学院长春应用化学研究所 | 2022-09-06 | — | — | CN | claimed |
| CN-112694453-A | Preparation method of N-methylated nitrogen-containing aromatic heterocyclic compound | 中国科学院长春应用化学研究所 | 2021-04-23 | — | — | CN | claimed |
| CN-111902415-A | Pharmaceutical compounds | 大冢制药株式会社 | 2020-11-06 | — | — | CN | claimed |
| US-20240336617-A1 | Substituted Bimane Compounds and Methods of Use Thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2024-10-10 | — | — | US | disclosed |
| WO-2024119866-A1 | BENZOTHIAZOLE PYRIMIDINEAMINE DYRK2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 江苏天士力帝益药业有限公司 | 2024-06-13 | — | — | WO | disclosed |
| CN-118146213-A | Benzothiazole pyrimidine amine DYRK2 inhibitor and preparation method and application thereof | 江苏天士力帝益药业有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-118005624-A | Pyrimidine benzo five-membered ring CDK inhibitor and preparation method and application thereof | 中国药科大学 | 2024-05-10 | — | — | CN | disclosed |
| EP-4282864-A1 | CDK6/DYRK2 DUAL-TARGET INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (CN) | 2023-11-29 | — | — | EP | disclosed |
| WO-2023222680-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2023-11-23 | — | — | WO | disclosed |
| US-20230303553-A1 | CDK6/DYRK2 DUAL-TARGET INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230203048-A1 | SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2018060689-A1 | CYANOPYRROLIDINE DERIVATIVES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2018-04-05 | — | — | WO | disclosed |
| EP-1477472-B1 | SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2009-01-14 | — | — | EP | disclosed |
| US-6867320-B2 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-03-15 | — | — | US | disclosed |
| EP-1477472-A1 | SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-03-04 | — | — | US | disclosed |
| EP-0003141-B1 | PROCESS FOR THE PREPARATION OF 2-AMINO-ARYLENOTHIAZOLE COMPOUNDS AND THEIR RING N-SUBSTITUTED DERIVATIVES | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-07-14 | — | — | EP | disclosed |
| US-4252963-A | CYCLIZATION OF PHENYLTHIOUREAS WITH THIONYL CHLORIDE | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-02-24 | — | — | US | disclosed |
| EP-0003141-A2 | Process for the preparation of 2-amino-arylenothiazole compounds and their ring N-substituted derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-07-25 | — | — | EP | disclosed |
| US-3994724-A | SUBSTITUTED ANILINE PHOTOCONDUCTOR | SCOTT PAPER COMPANY (US) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203048-A1 | SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, PKD1 | RAB9A 2264/4885NPC1 184/4885SMN1; SMN2 2615/4885 |
| US-20240336617-A1 | Substituted Bimane Compounds and Methods of Use Thereof | SNCA, PARK7, APP | RAB9A 1305/4885NPC1 3588/4885SMN1; SMN2 36/4885 |
| US-20230303553-A1 | CDK6/DYRK2 DUAL-TARGET INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CDK6, DYRK2, CDK16 | RAB9A 2905/4885NPC1 4073/4885SMN1; SMN2 1656/4885 |
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | PTGER1, CYSLTR1, PTGS1 | RAB9A 3743/4885NPC1 84/4885SMN1; SMN2 4713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.